AB
NKTR icon

Amalgamated Bank’s Nektar Therapeutics NKTR Stock Holding History

Amalgamated Bank’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed – – 2402
2025
Q4 		$0 Hold
1
– – ﹤0.01% 2991
2025
Q3 		$0 Hold
1
– – ﹤0.01% 3016
2025
Q2 		$0 Sell
1
-411
-100% -$4.62K ﹤0.01% 3092
2025
Q1 		$4K Hold
412
– – ﹤0.01% 2728
2024
Q4 		$6K Hold
412
– – ﹤0.01% 2677
2024
Q3 		$8K Hold
412
– – ﹤0.01% 2565
2024
Q2 		$8K Buy
+412
New +$8.68K ﹤0.01% 2566
2023
Q2 		– Sell
-4,926
Closed -$52K – 3090
2023
Q1 		$52K Sell
4,926
-313
-6% -$9.47K ﹤0.01% 2294
2022
Q4 		$178K Sell
5,239
-304
-5% -$14.7K ﹤0.01% 1904
2022
Q3 		$266K Buy
5,543
+194
+4% +$11.5K ﹤0.01% 1733
2022
Q2 		$305K Sell
5,349
-284
-5% -$17.9K ﹤0.01% 1694
2022
Q1 		$455K Buy
5,633
+1,684
+43% +$249K ﹤0.01% 1588
2021
Q4 		$800K Sell
3,949
-4,695
-54% -$1.02M 0.01% 1348
2021
Q3 		$2.33M Sell
8,644
-859
-9% -$207K 0.02% 858
2021
Q2 		$2.45M Buy
9,503
+8,057
+557% +$2.23M 0.02% 876
2021
Q1 		$434K Sell
1,446
-95
-6% -$29.6K 0.02% 1060
2020
Q4 		$393K Buy
1,541
+6
+0.4% +$1.55K 0.01% 1088
2020
Q3 		$382K Sell
1,535
-8
-0.5% -$2.52K 0.02% 990
2020
Q2 		$536K Sell
1,543
-1,054
-41% -$329K 0.02% 796
2020
Q1 		$695K Sell
2,597
-44
-2% -$13.6K 0.02% 758
2019
Q4 		$855K Buy
2,641
+177
+7% +$51.3K 0.02% 875
2019
Q3 		$673K Buy
2,464
+33
+1% +$12.1K 0.01% 912
2019
Q2 		$1.3M Buy
2,431
+864
+55% +$433K 0.03% 639
2019
Q1 		$790K Buy
1,567
+31
+2% +$18.4K 0.02% 803
2018
Q4 		$757K Sell
1,536
-42
-3% -$25.4K 0.02% 761
2018
Q3 		$1.44M Sell
1,578
-50
-3% -$42.7K 0.04% 502
2018
Q2 		$1.19M Buy
1,628
+121
+8% +$140K 0.03% 671
2018
Q1 		$2.4M Buy
1,507
+55
+4% +$70.9K 0.06% 303
2017
Q4 		$1.3M Buy
1,452
+87
+6% +$51.5K 0.04% 589
2017
Q3 		$491K Sell
1,365
-6
-0.4% -$1.88K 0.02% 952
2017
Q2 		$402K Buy
1,371
+110
+9% +$31.8K 0.01% 1045
2017
Q1 		$444K Sell
1,261
-2
-0.2% -$450 0.02% 904
2016
Q4 		$232K Buy
1,263
+262
+26% +$53.3K 0.01% 1303
2016
Q3 		$258K Hold
1,001
– – 0.02% 1111
2016
Q2 		$258K Buy
1,001
+78
+8% +$17.4K 0.01% 1109
2016
Q1 		$190K Buy
923
+82
+10% +$15.8K 0.02% 1162
2015
Q4 		$213K Sell
841
-82
-9% -$16.9K 0.03% 1024
2015
Q3 		$152K Buy
923
+16
+2% +$2.83K 0.02% 1201
2015
Q2 		$170K Buy
+907
New +$156K 0.02% 1266

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Amalgamated Bank's NKTR Position: Q1 2026 in Review

Amalgamated Bank sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 1 share.

Amalgamated Bank first reported a position in NKTR in Q2 2015 and held it in 39 quarters. The position peaked at $2.45M in Q2 2021. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Amalgamated Bank reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1 Nektar Therapeutics share in Q1 2026.
  • Amalgamated Bank first reported a position in Nektar Therapeutics in Q2 2015 and held it in 39 quarters.
  • Amalgamated Bank's Nektar Therapeutics position peaked at $2.45M in Q2 2021.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.